{
    "clinical_study": {
        "@rank": "89283", 
        "brief_summary": {
            "textblock": "RATIONALE: Biological therapies use different ways to stimulate the immune system and stop\n      cancer cells from growing. Combining different types of biological therapies may kill more\n      cancer cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating\n      patients who have myelodysplastic syndrome."
        }, 
        "brief_title": "Biological Therapy in Treating Patients With Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Leukemia", 
            "Myelodysplastic Syndromes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the frequency of hematologic responses in patients with myelodysplastic\n           syndrome treated with anti-thymocyte globulin and tumor necrosis factor receptor IgG\n           chimera.\n\n        -  Correlate phenotypic, cytogenetic, and functional disease characteristics with\n           treatment responses in these patients.\n\n        -  Determine the safety of this treatment regimen in this patient population.\n\n      OUTLINE: Patients receive anti-thymocyte globulin IV over 8 hours daily for 4 days followed\n      by tumor necrosis factor receptor IgG chimera subcutaneously twice weekly for 16 weeks.\n\n      Patients are followed at 8, 16, and 20 weeks.\n\n      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of myelodysplastic syndrome with no greater than 20% marrow blasts with:\n\n               -  Single or multilineage cytopenia (neutrophils less than 2,000/mm^3 and/or\n                  platelet count less than 100,000/mm^3 and/or reticulocyte count less than\n                  18,000/mm^3) OR\n\n               -  Transfusion requirement of at least 2 units packed red blood cells per month and\n                  one of the following:\n\n                    -  Suitable marrow donor unavailable\n\n                    -  Ineligible for a transplantation protocol\n\n                    -  Unwilling to proceed with transplantation\n\n          -  No chronic myelomonocytic leukemia\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Any age\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  See Disease Characteristics\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No other severe disease that would preclude study\n\n          -  No active severe infection (e.g., pneumonia or septicemia) or severe infections\n             within the past 2 weeks\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior hematopoietic growth factors\n\n          -  No concurrent hematopoietic growth factors\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior cytotoxic therapy\n\n          -  No concurrent cytotoxic therapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiation therapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 4 weeks since prior immunomodulatory therapy\n\n          -  No concurrent immunomodulatory therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005853", 
            "org_study_id": "1478.00", 
            "secondary_id": [
                "FHCRC-1478.00", 
                "NCI-G00-1793", 
                "CDR0000067878"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "anti-thymocyte globulin", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "etanercept", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "TNFR-Fc fusion protein"
            ]
        }, 
        "keyword": [
            "refractory anemia", 
            "refractory anemia with ringed sideroblasts", 
            "refractory anemia with excess blasts", 
            "refractory anemia with excess blasts in transformation", 
            "de novo myelodysplastic syndromes", 
            "previously treated myelodysplastic syndromes", 
            "secondary myelodysplastic syndromes", 
            "refractory cytopenia with multilineage dysplasia", 
            "childhood myelodysplastic syndromes"
        ], 
        "lastchanged_date": "March 31, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/FHCRC-1478.00"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center", 
            "last_name": "H. Joachim Deeg, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005853"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2010"
    }, 
    "geocoordinates": {
        "Fred Hutchinson Cancer Research Center": "47.606 -122.332"
    }
}